These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Chen F; Wang T; Wang J; Wang ZQ; Qian M Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092 [TBL] [Abstract][Full Text] [Related]
43. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related]
44. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Barkat MA; Beg S; Pottoo FH; Ahmad FJ Nanomedicine (Lond); 2019 May; 14(10):1323-1341. PubMed ID: 31124758 [TBL] [Abstract][Full Text] [Related]
45. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Bhat UG; Winter MA; Pearce HL; Beck WT Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894 [TBL] [Abstract][Full Text] [Related]
46. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Chiu LY; Ko JL; Lee YJ; Yang TY; Tee YT; Sheu GT Toxicol Lett; 2010 Feb; 192(3):408-18. PubMed ID: 19944135 [TBL] [Abstract][Full Text] [Related]
47. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Xing H; Wang S; Weng D; Chen G; Yang X; Zhou J; Xu G; Lu Y; Ma D Oncol Rep; 2007 Jan; 17(1):117-22. PubMed ID: 17143487 [TBL] [Abstract][Full Text] [Related]
48. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Si M; Zhao J; Li X; Tian JG; Li YG; Li JM Chin Med J (Engl); 2013 Nov; 126(21):4116-23. PubMed ID: 24229684 [TBL] [Abstract][Full Text] [Related]
49. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line. Wang C; Guo LB; Ma JY; Li YM; Liu HM Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547 [TBL] [Abstract][Full Text] [Related]
50. Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance. Zhang Y; Zhang YK; Wang YJ; Vispute SG; Jain S; Chen Y; Li J; Youssef DT; El Sayed KA; Chen ZS Mar Drugs; 2015 Apr; 13(4):2267-86. PubMed ID: 25874923 [TBL] [Abstract][Full Text] [Related]
51. Formulation effects on paclitaxel transfer and uptake in the human placenta. Ali S; Albekairi NA; Al-Enazy S; Shah M; Patrikeeva S; Nanovskaya TN; Ahmed MS; Rytting E Nanomedicine; 2021 Apr; 33():102354. PubMed ID: 33429062 [TBL] [Abstract][Full Text] [Related]
52. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077 [TBL] [Abstract][Full Text] [Related]
53. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery. Tam YT; To KK; Chow AH Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466 [TBL] [Abstract][Full Text] [Related]
54. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
55. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272 [TBL] [Abstract][Full Text] [Related]
56. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Zhang FF; Zhu YF; Zhao QN; Yang DT; Dong YP; Jiang L; Xing WX; Li XY; Xing H; Shi M; Chen Y; Bruce IC; Jin J; Ma X Eur J Pharmacol; 2014 Sep; 738():83-90. PubMed ID: 24877693 [TBL] [Abstract][Full Text] [Related]
57. Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel. Ruttala HB; Ramasamy T; Shin BS; Choi HG; Yong CS; Kim JO Int J Pharm; 2017 Mar; 519(1-2):11-21. PubMed ID: 28069389 [TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388 [TBL] [Abstract][Full Text] [Related]
59. Induction of fetal hemoglobin and ABCB1 gene expression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cells. Fyrberg A; Peterson C; Kågedal B; Lotfi K Cancer Chemother Pharmacol; 2011 Sep; 68(3):583-91. PubMed ID: 21110023 [TBL] [Abstract][Full Text] [Related]
60. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin. Singh MS; Lamprecht A Int J Pharm; 2015 Jan; 478(2):745-52. PubMed ID: 25437111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]